• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . SARS CoV-2 seroprevalence and rising antibody titres across successive pandemic waves in accra, Ghana: August 2020 to January 2022

tetano

Editor, Senior Moderator
Sci Rep


. 2026 Jun 22;16(1):19334.
doi: 10.1038/s41598-026-57566-3.
SARS CoV-2 seroprevalence and rising antibody titres across successive pandemic waves in accra, Ghana: August 2020 to January 2022

P J Pappoe-Ashong[SUP] 1 2 [/SUP], J A A Mingle[SUP] 3 [/SUP], D Tetteh[SUP] 3 [/SUP], C A Brown[SUP] 4 [/SUP], S K Nordzi[SUP] 5 [/SUP], B T Mensah[SUP] 4 [/SUP], J A Oliver-Commey[SUP] 6 [/SUP], P Puplampu[SUP] 7 [/SUP], C Jassoy[SUP] 8 [/SUP]


Affiliations
Abstract

Shortly after its first outbreak in Wuhan, the SARS CoV-2 spread worldwide. This study determined SARS CoV-2 seroprevalence and compared anti-RBD IgG titre distributions among seropositive samples across four repeated cross-sectional surveys conducted during successive epidemic waves from August 2020 to January 2022. Age-specific seroprevalence and titre patterns were also examined across children, adolescents, and adults. We conducted a seroepidemiological cross-sectional study over four epidemic waves periods. A stratified 1,096 samples, reflecting the age and sex distribution of the Accra population, was selected from 15,000 residual clinical samples. Adjusted seroprevalence increased from 58.3% (95% CI: 53.9-62.6%) in wave 1 to > 90% by wave 2 and remained ≥ 96% in waves 3 and 4. Adults aged ≥ 20 years reached near-universal seropositivity earlier than children, who accumulated exposure more gradually. Despite this early plateau, geometric mean anti-RBD IgG concentrations increased from 162 BAU/mL in wave 1 to 625 BAU/mL in wave 3, stabilising at 584 BAU/mL in wave 4. Analyses of antibody titre distributions demonstrated that progressively larger proportions of adults showed concentrations substantially exceeding wave 1 baseline levels in later waves, indicating age-related differences in cumulative antigenic exposure. Across successive epidemic waves, Accra experienced intense and repeated SARS CoV-2 transmission, resulting in near-universal exposure of the adult population by May 2021. Children and adolescents showed a slower and more gradual increase in both seroprevalence and antibody concentrations. Anti-RBD IgG titres increased across successive waves and stabilised after August-November 2021, consistent with sustained cumulative antigenic exposure at the population level.

Keywords: Antibody titres; Exposure; Ghana; SARS CoV-2; Seroprevalence; Sub-Saharan Africa.

 
Back
Top